Sernova Renews Frontier Flex for Canadian Investor Relations and Marketing
(TheNewswire)
LONDON, ONTARIO - TheNewswire – September 17, 2019 – Sernova Corp. (TSXV:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announces that it has renewed the engagement of Frontier Flex, an investor relations (IR) and marketing group based in Toronto, Ontario Canada to provide Canadian IR and strategic marketing services.
Sernova President and CEO Dr. Philip Toleikis commented, "Frontier remains an integral part of the communications strategy Sernova is implementing to increase Sernova’s visibility and help investors and shareholders stay well-informed as we advance our clinical programs including our US diabetes Phase I/II clinical study.”
Through their established network of financial industry professionals, marketing service providers, and outreach programs, FronTier will assist the corporation by increasing market awareness for the corporation using a number of financial market communications initiatives, including facilitating in-person introductions for the corporation with institutional and retail brokers in Toronto and other financial capitals, and through media distribution on national television, radio and multiple online channels.
Under the terms of the engagement, FronTier has been retained for a 12-month period for aggregate remuneration of $100,000 plus expenses. The agreement with Frontier Flex is subject to the approval of the TSX Venture Exchange.
In other news, Sernova has granted 6,980,000 stock options to certain officers, employees, and consultants of the company, each such option being exercisable into one common share at a price of $0.21 per share for periods ranging from 3 to 10 years, and has granted 3,120,167 DSUs to its directors.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Fax: (519) 858-5099
Toll-Free: (877)-299-4603
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Copyright (c) 2019 TheNewswire - All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
